CN Patent

CN103209691B — α-肾上腺素能受体激动剂在制备用于预防或治疗皮肤肿瘤的药物中的用途

Assigned to Galderma Research and Development SNC · Expires 2016-12-14 · 9y expired

What this patent protects

本发明涉及用于预防受试者中皮肤肿瘤形成或抑制受试者中存在的皮肤肿瘤发展的方法、组合物和产品。所述方法涉及向受试者施用含有α2肾上腺素能受体激动剂例如溴莫尼定的组合物。

USPTO Abstract

本发明涉及用于预防受试者中皮肤肿瘤形成或抑制受试者中存在的皮肤肿瘤发展的方法、组合物和产品。所述方法涉及向受试者施用含有α2肾上腺素能受体激动剂例如溴莫尼定的组合物。

Drugs covered by this patent

oxymetazoline-hydrochloride (OXYMETAZOLINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN103209691B
Jurisdiction: CN
Classification: —
Expires: 2016-12-14
Drug substance claim: No
Drug product claim: No
Assignee: Galderma Research and Development SNC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.